Tecentriq (atezolizumab) / Roche - LARVOL DELTA

MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - P1/2 | N=410 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2 • PD-L1 • TIGIT

CUPISCO: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (clinicaltrials.gov) - P2 | N=528 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Nov 2024

Trial completion • Trial completion date • Oncology

Development of JLF025, an anti-mesothelin T cell engager optimized for efficacy and safety (AACR 2025) - "In addition, combination of MSLN-490 with Atezolizumab or a chemotherapy drug paclitaxel produced a synergistic effect on tumor inhibition and more T cells were found infiltrated into tumors in the combo groups. In hMSLN and hCD3 double knock-in mouse, JLF025 demonstrated acceptable safety profiles. Thus, combination of JLF025 with immune checkpoint inhibitors and chemotherapy drugs represents a promising cancer treatment strategy and could be considered for future clinical trials."

Clinical • IO biomarker • Biliary Cancer • Breast Cancer • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • MSLN

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P3 | N=1000 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology

Humanistic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR) (ISPOR 2025) - "Four studies examined patients eligible for anti-PD-(L)1 therapy, and the remaining 9 studies examined all-comers (PD-(L)1 status unclear/mixed).Studies in anti-PD-(L)1 therapy eligible patients: These 4 studies compared atezolizumab+nab-paclitaxel versus placebo+nab-paclitaxel, pembrolizumab+chemotherapy versus placebo+chemotherapy, pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab+olaparib versus pembrolizumab+chemotherapy...One study showed HRQOL improvement and utility gains in later-line mTNBC for sacituzumab govitecan versus placebo/TPC... Newer therapies for mTNBC, including immunotherapy, showed no detriment or modest HRQOL benefit over comparators via exploratory analyses. More data are needed to better understand the humanistic burden of mTNBC on patient HRQOL, especially in the advanced/metastatic setting."

IO biomarker • Metastases • Review • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA

Primary results from EL1SSAR, a prospective phase 3b study of first-line atezolizumab (atezo) plus nab-paclitaxel (nPac) therapy for patients (pts) with PD-L1+ advanced triple-negative breast cancer (aTNBC) (ESMO-BC 2025) - No abstract available

Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

FAP-LTBR (RO7567132): A first-in-class bi-specific stromal immunomodulatory agonist designed to enable and enhance efficacy of cancer immunotherapies (AACR 2025) - P1 | "Treatment with the murine surrogate of RO7567132 led to tumor growth inhibition in a breast cancer model and showed greater efficacy when combined with the murine surrogate of atezolizumab in both breast cancer and fibrosarcoma models. Additionally, in a slow-growing orthotopic mouse colorectal cancer model, treatment with the murine surrogate of RO7567132 increased the content of immune cells (T and B cells) and HEVs in tumors and induced the formation of immune cell niches resembling TLS.RO7567132 was well tolerated in both a 2-week non-GLP Maximum tolerated dose/Dose range-finding (MTD/DRF) study and a 4-week GLP toxicology study in cynomolgus monkeys at doses up to 10 mg/kg, with no associated adverse findings.RO7567132 is currently being tested in an open-label, multicenter, dose-escalation, randomized, phase1 study (NCT06537310) to evaluate safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of RO7567132, as a single agent and in combination..."

Clinical • Immunomodulating • IO biomarker • Stroma • Breast Cancer • Colorectal Cancer • Fibrosarcoma • Oncology • Sarcoma • Solid Tumor • CXCL13 • TNFA

Comparative efficacy of cabozantinib or lenvatinib following atezolizumab plus bevacizumzb in patients with advanced hepatocellular cancer. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Analysis of atezolizumab immune-related adverse events based on the US FAERS database. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Adverse events • Palliative care

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study). (ASCO 2025) - "Clinical Trial Registration Number: JapicCTI-194849 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Efficacy and safety analysis of adjuvant atezolizumab in non-small cell lung cancer patients in China: A single center retrospective analysis. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Atezolizumab plus bevacizumab in combination with platinum based chemotherapy for ovarian cancer: A systematic review and meta-analysis of randomized control trials. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Combination therapy • Retrospective data • Review • Oncology • Ovarian Cancer • Solid Tumor

A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study). (ASCO 2025) - "Clinical Trial Registration Number: jRCTs051210148 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Evaluating the real-world impact of atezolizumab and bevacizumab combination in unresectable hepatocellular carcinoma: A south Indian experience. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Real-world • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor

Predictive values of sarcopenia for unresectable hepatocellular carcinoma treated with transarterial chemoembolization combining atezolizumab plus bevacizumab. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Hepatocellular Cancer • Oncology • Sarcopenia • Solid Tumor

Real-world data on the effectiveness and toxicity of atezolizumab and bevacizumab as first-line therapy in patients with unresectable or metastatic hepatocellular carcinoma in Costa Rica. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • Real-world • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor

Transarterial chemoembolization combined with atezolizumab plus bevacizumab versus transarterial chemoembolization combined with lenvatinib plus sintilimab as first-line therapy for advanced hepatocellular carcinoma. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • Hepatocellular Cancer • Oncology • Solid Tumor

Evaluation of the combination of lurbinectedin and atezolizumab in a humanized mouse model. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Preclinical

Real-world evidence on the efficacy of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: An institutional experience. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • HEOR • Real-world • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor

Comparing the bleeding risk in hepatocellular carcinoma patients treated with atezolizumab/bevacizumab versus durvalumab plus tremelimumab. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC). (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT03024996 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P3 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Using single-cell sequencing to identify endothelial expression of immune checkpoint ligands in advanced hepatocellular carcinoma, pre- and post- atezolizumab plus bevacizumab in the phase II INTEGRATE study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT04563338 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Engineering and preclinical development of an anti-TROP2/PD-L1 bispecific antibody drug conjugate (ADC) for enhanced anti-tumor efficacy (AACR 2025) - "Both anti-PD-L1 antibodies and TROP2-based antibody drug conjugates (ADCs) have shown significant clinical benefit, and a number of these agents, including atezolizumab and durvalumab (both anti-PD-L1 antibodies) and sacituzumab govitecan (an anti-TROP2-SN38 ADC), have been approved by the US FDA for certain cancer indications. In multiple xenografted tumor models, the bsAb ADC demonstrated greater tumor inhibitory activity than their respective monospecific parent antibody ADCs. Taken together, our findings support further development of this bsAb ADC for the treatment of multiple TROP2- and/or PD-L1-expressing cancers, and of those patients who are refractory and/or resistant to TROP2 or PD-L1 single target-based therapies."

Preclinical • Oncology • TACSTD2